[Consensus on linezolid in the treatment of tuberculosis(2022 update)].

Linezolid is the core drug for the treatment of multidrug-resistant tuberculosis. In 2018, Chinese Society for Tuberculosis, Chinese Medical Association(CSTB) issued a "consensus on linezolid in the treatment of tuberculosis". With the wider use of it in clinic, the improved understanding and the progress in research, CSTB organized experts to update this consensus and formed "consensus on linezolid in the treatment of tuberculosis(2022 update)", with a view to play a guiding role for clinicians. The consensus included the molecular structure and mechanism of action, pharmacodynamics, pharmacokinetics, clinical application, indications, contraindications and relative contraindications, dosage, usage and formulation of chemotherapy regimen, adverse reactions and clinical application. In this edition, we updated the drug resistance mechanism of linezolid, and the medical evidence was rated and recommended according to the grading of recommendations assessment, development and evaluation (GRADE) method.利奈唑胺是治疗耐多药结核的核心药物。2018年中华医学会结核病学分会发布了《利奈唑胺抗结核治疗专家共识》。随着利奈唑胺在临床广泛使用、临床医生对利奈唑胺认识的提高以及研究取得更多进展，中华医学会结核病学分会再次组织专家对此共识进行了更新，形成《利奈唑胺抗结核治疗专家共识（2022年版）》，以期对临床工作发挥指导作用。共识中包含了利奈唑胺的分子结构与作用机制、药效学研究、药代动力学研究、临床应用研究、适应证、禁忌证及相对禁忌证、剂量、用法及化疗方案的制定、不良反应和临床应用注意事项几部分。这一版更新了利奈唑胺的耐药机制，并根据推荐意见分级的评估、制订及评价（GRADE）方法对医学证据评级和进行推荐。.